These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 7083769)

  • 41. Pharmacokinetics of salicylate and indomethacin in coeliac disease.
    Parsons RL; Kaye CM; Raymond K
    Eur J Clin Pharmacol; 1977 Jul; 11(6):473-7. PubMed ID: 891594
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Partial metabolic clearances as determinants of the oral bioavailability of propranolol.
    Walle T; Walle UK; Olanoff LS; Conradi EC
    Br J Clin Pharmacol; 1986 Sep; 22(3):317-23. PubMed ID: 3768243
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Studies of the absorption and removal of propranolol in hypertensive patients during therapy.
    Chidsey CA; Morselli P; Bianchetti G; Morganti A; Leonetti G; Zanchetti A
    Circulation; 1975 Aug; 52(2):313-8. PubMed ID: 1149212
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Protein synthesis by cultured jejunal mucosa from control subjects and patients with coeliac disease.
    Jones PE; L'Hirondel CL; Peters TJ
    Gut; 1981 Aug; 22(8):623-7. PubMed ID: 7286778
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of acute alcohol administration on propranolol absorption.
    Grabowski BS; Cady WJ; Young WW; Emery JF
    Int J Clin Pharmacol Ther Toxicol; 1980 Jul; 18(7):317-9. PubMed ID: 7429677
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Brain availability of monoamine precursors in adult coeliac disease.
    Hallert C; Mårtensson J; Allgén LG
    Scand J Gastroenterol; 1982 Jan; 17(1):87-9. PubMed ID: 7134841
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Assessment of jejunal function in patients with dermatitis herpetiformis and adult coeliac disease using a perfusion technique.
    Kumar PJ; Silk DB; Rousseau B; Pagaltsos AS; Clark ML; Dawson AM; Marks R
    Scand J Gastroenterol; 1974 Nov; 9(8):793-8. PubMed ID: 4432052
    [No Abstract]   [Full Text] [Related]  

  • 48. Reduction of liver blood flow and propranolol metabolism by cimetidine.
    Feely J; Wilkinson GR; Wood AJ
    N Engl J Med; 1981 Mar; 304(12):692-5. PubMed ID: 7464861
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Influence of physical exercise on the pharmacokinetics of propranolol.
    Arends BG; Böhm RO; van Kemenade JE; Rahn KH; van Baak MA
    Eur J Clin Pharmacol; 1986; 31(3):375-7. PubMed ID: 3792439
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Interactions of phenobarbital with propranolol in the dog. 2. Bioavailability, metabolism and pharmacokinetics.
    Vu VT; Bai SA; Abramson FP
    J Pharmacol Exp Ther; 1983 Jan; 224(1):55-61. PubMed ID: 6848749
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Changes in jejunal permeability and passive permeation of sugars in intestinal biopsies in coeliac disease and Crohn's disease.
    Dawson DJ; Lobley RW; Burrows PC; Notman JA; Mahon M; Holmes R
    Clin Sci (Lond); 1988 Apr; 74(4):427-31. PubMed ID: 3128419
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Propranolol absorption.
    George CF; Castleden M
    Br Med J; 1977 Jan; 1(6052):47. PubMed ID: 831986
    [No Abstract]   [Full Text] [Related]  

  • 53. Drug absorption and metabolism studies by use of portal vein infusion in the rat. II. Influence of dose and infusion rate on the bioavailability of propranolol.
    Suzuki T; Isozaki S; Ishida T; Saito Y; Nakagawa F
    Chem Pharm Bull (Tokyo); 1974 Jul; 22(7):1639-45. PubMed ID: 4434590
    [No Abstract]   [Full Text] [Related]  

  • 54. Absorption kinetics of sublingually administered propranolol.
    Kates RE
    J Med; 1977; 8(6):393-402. PubMed ID: 272433
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Pharmacodynamic half-life of KO 1366 administered by intravenous and oral route. Comparison with propranolol].
    Hugues FC; Mougeot G; Munera Y; Julien D; Marche J
    Therapie; 1978; 33(3):267-75. PubMed ID: 28580
    [No Abstract]   [Full Text] [Related]  

  • 56. Influence of vitamin C on the absorption and first pass metabolism of propranolol.
    Gonzalez JP; Valdivieso A; Calvo R; Rodríguez-Sasiaín JM; Jimenez R; Aguirre C; du Souich P
    Eur J Clin Pharmacol; 1995; 48(3-4):295-7. PubMed ID: 7589058
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nasal absorption of propranolol in rats.
    Hussain AA; Hirai S; Bawarshi R
    J Pharm Sci; 1979 Sep; 68(9):1196. PubMed ID: 501554
    [No Abstract]   [Full Text] [Related]  

  • 58. [Study of bioavailability parameters of propranolol in cirrhotic patients after oral administration of the delayed-action form].
    Blanc M; Cales P; Grasset D; Ravaud A; Meskens C; Cotonat J; Pascal JP
    Therapie; 1987; 42(2):187-91. PubMed ID: 3616995
    [No Abstract]   [Full Text] [Related]  

  • 59. Glutathione S-transferases in small intestinal mucosa of patients with coeliac disease.
    Wahab PJ; Peters WH; Roelofs HM; Jansen JB
    Jpn J Cancer Res; 2001 Mar; 92(3):279-84. PubMed ID: 11267937
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Decreased absorption as a possible cause for the lower bioavailability of a sustained-release propranolol.
    Takahashi H; Ogata H; Warabioka R; Kashiwada K; Ohira M; Someya K
    J Pharm Sci; 1990 Mar; 79(3):212-5. PubMed ID: 2338628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.